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development. Rather than creating a separate disease entity, 
we recommend the continued use of an analytical approach 
based on NFT stages and Aβ phases with no inference 
about hypothetical disease processes.
Keywords Alzheimer disease · Amyloid ·  
Aβ · PART hypothesis · Tau · Tauopathy
Introduction
Tau aggregation in nerve cell bodies (neurofibrillary 
tangles, NFTs) and neurites (neuropil threads and the 
Abstract It has been proposed that tau aggregation con-
fined to entorhinal cortex and hippocampus, with no or 
only minimal Aβ deposition, should be considered as a 
‘primary age-related tauopathy’ (PART) that is not inte-
gral to the continuum of sporadic Alzheimer disease (AD). 
Here, we examine the evidence that PART has a pathogenic 
mechanism and a prognosis which differ from those of AD. 
We contend that no specific property of the entorhinal–hip-
pocampal tau pathology makes it possible to predict either 
a limited progression or the development of AD, and that 
biochemical differences await an evidence base. On the 
other hand, entorhinal–hippocampal tau pathology is an 
invariant feature of AD and is always associated with its 
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coronae of neuritic plaques) constitutes the tau pathology 
of Alzheimer disease (AD). Aggregated Aβ accumulates 
extracellularly as diffuse or focal deposits. The severity 
of AD-related tau and Aβ pathologies is routinely evalu-
ated by their distribution patterns in the brain in addition 
to the density of neuritic plaques (ABC score [17, 22]). 
Tau pathology, in the context of AD, follows a hierarchi-
cal distribution, occurring in ordered sets of regions: It can 
be found in the entorhinal cortex alone, in the entorhinal 
cortex and the hippocampus, or in the entorhinal cortex, 
the hippocampus, and the neocortex [1]. Aβ deposits can 
be found in the neocortex alone, in the neocortex and the 
hippocampus, or, in addition, in the basal ganglia, the mes-
encephalon, and the cerebellum [26]. The number of areas 
that are involved in tau and Aβ pathology increases contin-
ually in a definite sequence. This observation indicates that 
the accumulation, be it of tau or of Aβ, is not or only mini-
mally cleared. It also implies a progression independent of 
lesion density. This is the basis of the neurofibrillary tangle 
(NFT) stages (assessing tau pathology) [1, 2] and of the Aβ 
phases (assessing Aβ deposits) [26].
Crary et al. [8]. suggest creating a separate neurode-
generative disease called PART (‘primary age-associated 
tauopathy’) that describes cases with tau pathology in the 
entorhinal cortex and hippocampus (ECH tau pathology) 
either without Aβ deposits (tau+/Aβ-) or with minimal 
Aβ deposits. The number of Aβ deposits that is compatible 
with PART and the techniques used to detect them remain 
to be determined. It is proposed that such topographically 
limited tau pathology is ‘age-related’ but unrelated to AD. 
These cases are characterized by a low NFT stage (I–III or 
IV) with no or little Aβ deposition (Aβ phase 0 to 2), or tau/
Aβ I/0, tau/Aβ II/0, etc., with the first score here signifying 
the NFT stage, the second the Aβ phase, and tau/Aβ as the 
abbreviation for tau pathology/Aβ deposits.
PART and ECH tau pathology
There is consensus regarding the high prevalence of tau 
pathology in the ECH without amyloid deposition (tau/Aβ 
I/0, II/0, III/0, and, rarely, IV/0). Two main hypotheses cur-
rently exist for integrating such cases nosologically: One 
favors unity, i.e., a continuum from tau+/Aβ− to tau+/
Aβ+; the PART concept posits a duality of processes, 
AD vs ‘aging’, with age-associated tauopathy (tau+/Aβ-) 
defining PART and considered to be a process different 
from AD-associated tau+/Aβ+.
According to the PART hypothesis, tau+/Aβ- cases 
have a condition that differs from AD and would not have 
reached NFT stages higher than IV and Aβ phases greater 
than 2, even if they had lived longer. According to the same 
hypothesis, tau pathology is associated with aging, whereas 
Aβ deposition is linked to AD with the inference that very 
old people should be spared by the latter and affected by 
the former. If tau pathology is indeed constant in cente-
narians, so too is Aβ deposition [10]––an observation that 
contradicts the supposed distinction between aging and AD 
pathology.
In view of the new possibilities for imaging tau pathol-
ogy and Aβ deposits, it is probable that advances in neuro-
imaging will enable us to answer, in the future, the question 
of the unity or duality of these pathologies. Very elderly 
people will have to be included in such studies to cope with 
the long duration, and possibly uneven progression, of tau 
and Aβ pathologies. A distinction will have to be made 
between the increase in the local density of the lesions with 
age and the increase in the number of affected regions. The 
prognostic value of quantified ECH tau pathology across 
the aging spectrum will be a major issue. According to 
the PART hypothesis, tau pathology in the ECH, when it 
is not accompanied by Aβ deposition, will not progress (or 
is less likely to progress). Alternatively, if the continuum 
hypothesis is correct, the risk of developing AD will be 
significantly increased in cases with ECH tau pathology, 
and ECH tau pathology will always precede full-blown AD 
within a time period that remains to be determined. From 
a mechanistic point of view, the PART and tau continuum 
hypotheses suggest fundamental differences. If ECH tau 
pathology, which, according to the PART hypothesis, is not 
integral to AD, is in fact part of the early stages of AD, then 
the amyloid cascade hypothesis will have to be amended.
The continuum hypothesis does not exclude the pos-
sibility that a specific tauopathy affects the hippocampus 
with particular severity and causes marked neuronal loss 
at a stage where the number of involved regions is limited 
(local severity with limited extension). Such cases should 
be detected in the future by comparing the local severity of 
the lesions in the hippocampus with the NFT stage––this 
comparison is not performed in the current PART criteria. 
Such cases, which at first approximation may be rare, are 
confused with early AD cases using the proposed PART 
criteria: Indeed, most of the tau+/Aβ- cases appear to be a 
stage of AD rather than a specific form of disease, accord-
ing to the continuum hypothesis that is developed here.
PART and SNAP
The attempt to isolate PART, with its combination of 
changes (tau+/Aβ−) differing from the combinations 
tau−/Aβ+ and tau+/Aβ+ thought to characterize AD, is 
reminiscent of the recent classification, based on biomarker 
profiles, of cases with normal Aβ biomarker values but 
with “brain injury biomarkers” or “neuronal injury bio-
markers” (including elevated CSF tau and phospho-tau), a 
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combination that does not fit the anticipated progression, 
i.e., an abnormal level of CSF Aβ (stage 1), associated with 
brain injury biomarkers (stage 2), and, finally, with subtle 
cognitive impairment (stage 3) [21, 25]. These cases have 
been assigned to the “suspected non-Alzheimer pathophys-
iology” (SNAP) group. One is inclined to equate SNAP 
(brain injury+/Aβ- biomarkers) and PART (tau+ and Aβ− 
pathologies at post-mortem)––as recently discussed [19]. It 
is beyond the scope of this paper to address the question 
(the interested reader is referred to [19]), but the reasons 
leading to the isolation of SNAP and PART are strikingly 
similar. We will confine our discussion to the sequence of 
tau and Aβ pathologies in AD and to the relevance of iso-
lating PART as a specific entity. Some of the conclusions 
drawn here regarding PART, however, could apply in the 
future to SNAP: the sequence of biomarker changes pro-
posed by Jack in SNAP, for instance, is also relevant to 
PART [19].
Possible benefits of the PART hypothesis
Several reasons have been proposed for isolating PART 
from the continuum of AD. The first rests upon practical 
advantages. PART can facilitate communication among 
pathologists, clinicians, and researchers; it can separate 
pathologic classification from clinical diagnosis; and it 
can also help neuropathologists to avoid using the term 
dementia. These reasons are not compelling. Crary et al. 
[8] believe that PART is sufficient to span the tau/Aβ indi-
ces from I/0 to IV/0, but the term has the obvious disad-
vantage of a loss of information: The stages and phases 
reflect greater diversity than can be subsumed under the 
PART umbrella. On the other hand, adding the PART label 
to the tau/Aβ indices I or II/0, 1 or 2, as recommended by 
Crary et al., does not add any information because PART 
is used synonymously with the tau/Aβ indices. The term 
PART simply implies that the neuropathologist takes an 
option about the putative prognosis and pathogenesis of 
these indices. The current practice of NFT stages and Aβ 
phases already separates pathology from clinical diagnosis 
and prevents the neuropathologist from using the clinical 
term of dementia in his/her diagnoses: NFT stages and Aβ 
phases are, in fact, staging procedures and not diagnostic 
criteria.
Additional reasons that pertain to the question of the 
existence of a specific pathology different from that of AD 
have been put forward [8]:
1. The average age at death is generally higher for PART 
patients than for those with AD.
2. There is no association of PART with the APOEε4 
allele. An association with the tau H1 haplotype has 
been found in ‘tangle-predominant’ forms of AD, 
which are now subsumed under the PART umbrella.
3. The more severe PART pathology is associated with a 
higher age at death and lower scores on cognitive tests.
These points will be discussed later. We contend first 
that there is no way, neuropathologically, genetically, or 
clinically, to differentiate PART from early AD.
No characteristics of the tau pathology permit the 
independent diagnosis of PART from preclinical/early 
AD
The PART hypothesis raises questions that are currently 
impossible to resolve (Fig. 1). In the continuum hypothesis, 
tau pathology begins in the ECH (NFT stages I to III or 
IV) in the absence of Aβ deposits (Aβ phase 0); tau pathol-
ogy is later found in the isocortex (NFT stages V and VI) 
together with Aβ deposits (Aβ phase 1 or higher). Tau dep-
osition in the ECH is necessary but not sufficient for the 
development of AD.
The intrinsic properties of tau aggregation are identical 
in the early and late NFT stages. According to the PART 
hypothesis, ‘age-related’ medial temporal lobe NFTs – 
occurring in the absence of Aβ deposition––differ from 
AD-related NFTs––associated with Aβ deposition. The 
attribution of different diagnoses to the same inclusions 
(ECH tau pathology) based upon extrinsic characteristics 
(presence or absence of AD-associated Aβ deposits) could 
well be less effective than regrouping under the same term 
similar inclusions that have different extrinsic characteris-
tics, as has recently been done for “tauopathies,” “synucle-
inopathies,” or “fronto-temporal lobar degeneration-TDP-
type.” Moreover, the extrinsic characteristics that permit 
the diagnosis of PART raise questions that two hypothetical 
examples will help to illustrate.
AD at onset cannot be distinguished from PART with a low 
number of Aβ deposits
In the first example, AD develops in a patient who was not 
previously affected by PART. Will the Aβ deposits first be 
found in isolation (NFT stage 0, Aβ phases 1 or higher)? 
In our experience, isolated Aβ deposition (without any 
tau pathology) is exceptional in large cohorts in which tau 
aggregation and Aβ deposition have been systematically 
studied [3], whereas tau deposition in ECH is the most 
common pathology with increasing age. We are surprised 
by the high prevalence of ‘low,’ ‘moderate,’ or even ‘high’ 
plaque scores at NFT stage 0 in Crary et al. [8]. As a rule, 
some tau pathology is found in the ECH when Aβ is found 
in the isocortex. How will that situation (NFT stages I, II, 
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III/Aβ phases 1 or higher), occurring at the onset of AD, 
be distinguished from PART? Or does AD (in contrast to 
PART) induce a tauopathy that involves at once the isocor-
tex and the ECH without progression––with the unexpected 
consequence that low NFT stages should always be consid-
ered to be age-related?
PART with AD cannot be distinguished from AD
In the second example, a patient develops PART and, 
later, AD. An “age-related” tauopathy is initially found in 
the ECH (NFT stages I, II, or III). At the onset of AD, Aβ 
deposits appear in the isocortex (Aβ phase 1). Does the 
“age-related” tauopathy that was initially present in ECH 
still qualify as PART as soon as Aβ deposition occurs, 
or does it become AD-related since it loses its status of a 
“pure tauopathy,” which defines PART? The logic would 
be to consider, despite the term “pure,” that PART remains 
PART even when AD starts to develop. Should it be consid-
ered then that ECH tau pathology is mixed (AD- and “age-
related”), but that their components cannot be separated 
because there is, at least currently, no way to distinguish 
between AD and age-related tau aggregation? Should it be 
considered, on the contrary, that tau pathology, inasmuch 
as it involves the ECH, always belongs to PART with the 
unexpected consequence of excluding from AD pathology 
the lesions in the hippocampus that continue to worsen dur-
ing the course of AD? As seen from the examples above, 
neither the topography nor the intrinsic properties of the 
tauopathy enable one to separate “age-related” and AD-
related processes.
In the elderly, Aβ deposition is linearly proportional 
to NFT stages, with no inflection caused by PART
Once cases harboring genes that enhance early Aβ deposi-
tion are excluded from the population, the number of cases 
with Aβ accumulation and signs of ‘neurodegeneration’ is 
linearly proportional to age in vivo [20]. The difficulties in 
separating ‘age-related’ from AD-related processes are illus-
trated by Table 1 from Crary et al. [8] in which cases with 
Aβ deposition in the cortex (phase 1) or in the hippocampus 
(phase 2)––i.e., cases with tau/Aβ I/1 or III/2—are classi-
fied as Pure Age Related Tauopathy (PART), a contradiction 
in terms. According to the PART hypothesis, the presence 
of Aβ deposits speaks for the presence of an AD-related 
process rather than a pure tauopathy. Biochemical analysis 
of the isocortex has revealed, however, the presence of Aβ 
aggregates that were not detected by immunohistochemis-
try at low NFT stages [9]. A significant proportion of PART 
cases in Table 1 of Crary et al. [8] exhibits a low-plaque 
score considered compatible with possible PART––up 
to 35 % of the cases in NFT stage II. But is it justified to 
separate the ‘low’ plaque scores as compatible with possi-
ble PART from the ‘moderate’ and ‘high’ scores that would 
be related to AD? The pooled prevalence of cases with 
‘low,’ ‘moderate,’ and ‘numerous’ amyloid plaque scores 
in Table 1 of Crary et al. [8], with no distinction of possi-
ble PART cases from the whole population, appears to be 
strongly linked with the NFT stage. The correlation between 
the NFT stage and the proportion of cases with at least a low 
amyloid plaque score in Crary et al. [8] (r = 0.989) or Aβ 
deposition at least at phase 1 in Braak and Del Tredici [4] 
(r = 0.995) is close to 1––the high value of r indicating 
that it is possible to predict with a high degree of precision 
the proportion of cases with Aβ pathology only from the 
value of the NFT stage (Fig. 2). The probability of having 
the cases with AD and the cases with PART aligned if two 
Fig. 1  Relationship between the development of tau pathology and 
Aβ deposition. a Tau pathology in the entorhinal cortex and hip-
pocampus (ECH) belongs to the AD continuum. It is complemented 
over time by Aβ deposition that occurs in an ordered manner (no 
attempt has been made to represent the duration of each stage or 
phase; only the sequence is important here). b Panel b illustrates the 
PART hypothesis and the issues it raises. Tau pathology in the ECH 
differs from tau pathology in AD, with three major problems indi-
cated by the dotted lines. 1 Can Aβ deposition precede tau pathology? 
2 Can tau pathology related to PART occur with Aβ deposition phases 
1–2? 3 How and where does PART end? Panel a describes our posi-
tion
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independent processes were to be involved is extremely low. 
If there were to be two pathogenic processes, the slopes and 
intercepts should have been different at low (supposedly 
falling under the diagnosis of PART) and high (supposedly 
falling under the diagnosis of AD) NFT stages.
Correlation is not causality: It may be taken as evidence 
of Aβ pathology causing or promoting tau pathology, of 
tau pathology causing or promoting the development of 
Aβ pathology, or of a third (currently unknown) variable 
responsible for the synchronous development of the two 
pathologies. However, the comparison of the two curves 
linking the proportion of cases with Aβ pathology and NFT 
stage shows a remarkable difference between the data of 
Crary et al. [8]. and of Braak and Del Tredici [5]: In the first 
dataset, a high proportion of NFT 0 cases have Aβ plaques, 
whereas in the second dataset there is no case with Aβ that 
has no tau pathology (Fig. 2a). Moreover, the slopes are, 
although not identical, very similar (Fig. 2b). The differ-
ence in datasets may, in our view, be given two opposing 
interpretations: Either Crary et al. do not detect NFT stages 
I and II and the curve representing their data has to be 
translated along the X-axis (red arrows in Fig. 2a), or Braak 
and Del Tredici do not detect Aβ deposits with as high a 
sensitivity as Crary et al. and the curve representing their 
dataset has to be translated along the Y axis (blue arrows 
in Fig. 2a). We favor the first explanation: The ‘amyloid 
plaque score’ was obtained with different methods in the 
cohort of Crary et al. [8]. Using thin sections, while thick 
sections with larger areas were examined using a sensitive 
silver method (Campbell–Switzer) in the cohort of Braak 
and Del Tredici [5]. On the other hand, the tissue sample 
should include the entorhinal cortex, i.e., must involve the 
most anterior portion of the hippocampus, to detect NFT 
stages I and II accurately [1]—a sample not commonly 
used in routine practice––and, finally, AT8 immunohisto-
chemistry (one of the most sensitive techniques for detect-
ing tau pathology used by Braak and Del Tredici [5]) is 
not mandatory in the NIA-AA criteria [17, 22]. It should 
be added that the debate could be resolved by an exchange 
of slides from early stages and phases. The question of the 
precedence of tau or of Aβ pathology could have important 
implications for the identification of therapeutic targets.
In the final analysis, the relationship between the propor-
tion of cases with Aβ pathology and the NFT stage here is 
linear. No inflection in the curve suggests the occurrence of 
different pathogenic processes, such as PART, that would 
change the slope of the curve [8]. The percentage of ‘pure’ 
PART cases thus decreases linearly with the NFT stage, a 
proportionality that argues in favor of a continuum between 
tau+/Aβ− cases and tau+/Aβ+ cases. The most succinct 
explanation for the distribution of tau and Aβ pathologies 
in AD is a progression that begins with tau pathology in the 
ECH, followed by Aβ deposition in the isocortex, and ends 
with the gradual propagation of tau pathology to the isocor-
tex. The time course of this progression is slow and cannot 
be predicted at present. The PART hypothesis artificially 
divides the progression (see Fig. 3).
Fig. 2  Linear relationship between the NFT stage and the propor-
tion of cases with Aβ pathology. a Raw data from Crary et al. [8] 
(red squares) and Braak and Del Tredici [5] (blue diamonds). The 
red squares indicate the percentage of cases with ‘low,’ ‘moder-
ate,’ or ‘high’ amyloid plaque score. The blue diamonds indicate 
the percentage of cases with Aβ phases 1, 2, 3, 4 or 5. Red squares 
and blue diamonds thus refer to the cases with Aβ deposition, what-
ever its severity. The blue arrows indicate the translation along the Y 
axis that should be applied to Braak and Del Tredici data [5] so that 
they coincide with the Crary et al. data [8]. The red arrows indicate, 
alternatively, the translation that should be applied along the X axis 
so that the Crary et al. data [8] coincide with Braak and Del Tredici 
data [5] (see text for explanation). b Regression line between the NFT 
stages and the proportion of cases with Aβ pathology. To compute 
the correlation coefficient, the slope and the intercept of the regres-
sion lines, the NFT stages (I to IV) had to be translated into numeri-
cal value (1–4). Equation of the red line (data from Crary et al. [8]): 
Proportion of cases (in percentage) with low, moderate or high plaque 
score = 11.78 × NFT stage + 46.5. The correlation coefficient 
r = 0.99 indicates that the NFT value suffices to predict with a high 
degree of accuracy the proportion of cases with Aβ pathology. Equa-
tion of the blue line (data from Braak and Del Tredici) [5]: Proportion 
of cases (in percentage) with Aβ phase higher than 0 = 18.21 × NFT 
stage + 3.11. The correlation coefficient r = 0.995 indicates that the 
NFT stages almost fully predicts the proportion of cases with Aβ 
pathology
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No clinical or genetic characteristics permit the 
differentiation of PART from preclinical/early AD
Crary et al. [8] suggest that patients with PART have spe-
cial genetic characteristics. We think that the dataset pre-
sented by Crary et al. [8] are not convincing in that respect 
and can be interpreted within the framework of a contin-
uum from tau/Aβ I/0 to tau/Aβ VI/5. Since the number of 
cases per diagnostic category in Table 1 of Crary et al. [8] 
is small, conclusions should be drawn with caution. With 
this caveat in mind, the statement that the age at death for 
patients with PART is higher than for those with AD is 
not supported by Table 1 of Crary et al. [8]. Comparisons 
were made there between NFT stage 0 and the other stages 
(the mean age of death did indeed increase with stage), but 
comparisons were not made within the columns for each 
stage between the cases with and without Aβ deposits. The 
differences were small, and usually––but not always––indi-
cated a younger age of the patients with Aβ deposits, but 
this could have been driven by the ApoE ε4 allele.
Crary et al. [8] claim that “there is an absence of an asso-
ciation between PART and the strongest risk factor for AD, 
the APOE ε4 allele,” but the data supplied in their Table 1 
do not support this statement. Instead, they indicate that the 
ApoE ε4 allele is more frequent in PART ‘definite’ cases 
(amyloid plaque density = none) at NFT stages I, III, and 
IV than in normal cases at NFT stage 0. Although not sta-
tistically significant, these results indicate that even defi-
nite PART cases do not show any tendency towards a lower 
ApoE ε4 frequency. In line with this, the frequency of the 
APOE ε4 allele had previously been reported to be higher in 
NFT stage I cases than in stage 0 cases in a cohort of patients 
in which the comparison reached significance, suggesting an 
influence of ApoE ε4 even on the development of early tau 
pathology [14]. Cases with PART ‘possible’ at NFT stages 
IV have, again, a higher ApoE ε4 allele frequency than cases 
with low AD-related changes (i.e., low amyloid plaque den-
sity and NFT stage 0), and the value reaches significance if 
we understand the legend accompanying Table 1 of Crary 
et al. that states that all comparisons were made with “Braak 
NFT stage 0 cases” (although one value labeled as signifi-
cant is in the Braak NFT stage 0 column) [8].
Fig. 3  Relationship between the NFT stage and the proportion of the 
population with an ‘amyloid plaque score’ of ‘none’ (PART definite), 
‘low’ (PART possible), and ‘high’ (‘AD neuropathologic changes’). 
Comparisons with NFT stages and Aβ phases. Area chart. The per-
centage of the population (y value) corresponding to the NFT stage 
(X axis) for each category (color and label shown on each area) is 
proportional to the length of its projection on the Y axis. a The val-
ues shown here have been calculated from Table 1 of Crary et al. [8]. 
Percentage of normal cases (green) = NFT stage 0, amyloid plaque 
score = none. The PART area is surrounded by a dotted yellow line. 
Percentage of cases with PART ‘definite’ (yellow) = NFT stage > 0, 
amyloid plaque score = none. Percentage of cases with PART ‘pos-
sible ‘(dark yellow) = NFT stage > 0; amyloid plaque score = low. 
AD neuropathological changes [22] are indicated in shades of red, 
with a red border. The red and white cross-hatching corresponds to 
an area extrapolated from Table 1 of Crary et al. [8]: The diagnosis 
is necessarily AD neuropathological changes because NFT stages are 
>4 with a ‘moderate’ or ‘high’ plaque score. The blue arrow indicates 
the progression of Alzheimer disease neuropathological changes as 
we understand them in the context of the PART hypothesis: PART 
cases do not commonly progress to Alzheimer disease. Alzheimer 
disease begins with a low plaque count (or low Aβ phase) in the 
absence of tau pathology in the ECH. Please note that the frequency 
of cases with NFT stage 0 and ‘amyloid plaques’ (up to ‘numerous’ 
plaque score) is low in our experience (see text and [3]). It should 
also be emphasized that the dividing line between PART ‘definite’ 
and ‘possible’, and between PART ‘possible’ and AD-related changes 
is in Table 1 of Crary et al. [8] relies on an “amyloid plaque score” 
that differs from the “neuritic plaque score” recommended in the 
NIA–AA criteria [22] and from the Aβ phases recommended in the 
PART diagnostic criteria proposed in Table 2 of Crary et al. [8]. The 
difference between the density of neuritic plaques and of all types of 
Aβ deposits may be considerable. b The values shown here have been 
calculated from the cohort presented in Braak and Del Tredici [4]. 
Normal (green) = NFT stage 0, plaque score = none. The proportion 
of cases in the observed combination of NFT stages and Aβ phases 
are indicated in red shading. The blue arrow indicates the progression 
of the changes in the context of the continuum hypothesis defended 
here
▸
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The data in the literature concerning the H1 haplotype 
of MAPT, the tau gene, indicate multiple effects. It is well 
established that H1 is associated with progressive supra-
nuclear palsy (PSP) and corticobasal degeneration (CBD), 
two diseases with tau inclusions, as well as with Parkinson 
disease [13]. It has also been reported that the H1c haplo-
type increases the risk of AD [24]. Tau pathology and the 
density of Aβ plaques are less severe with the H1 tau haplo-
type, both in early- and in late-stage cases of AD [23, 27]. 
Current data thus indicate that the H1 haplotype modulates 
the risk of AD as well as the severity of the pathology, but 
there is no evidence that it can be taken as a specific marker 
of PART. Of course, larger datasets and agreement on com-
parator groups are needed to ascertain any differences in 
genotype between different types of cohorts, whether those 
considered to be progressing along a continuum, or those 
considered as having dichotomous disease processes.
PART and experimental seeding/spreading of tau 
pathology
Arguments for and against each hypothesis will probably 
remain unsatisfactory in the absence of a pathophysiologi-
cal mechanism. Why are Aβ and tau pathologies intermin-
gled and what is their causal relationship? Why do they 
progress? It should be emphasized that, experimentally, the 
progression of tau pathology in a prion-like manner is not 
confined to the ECH [6, 7, 12, 15, 18], nor does the spread-
ing of aggregated tau require the presence of Aβ deposits. 
The involvement of the brainstem and the spinal cord has 
been observed at NFT stage I [11, 16]. It has to be deter-
mined which differences, molecular or otherwise, could 
explain why the tangles of PART should remain confined 
to the ECH, whereas the tangles of AD would be capable 
of inducing the spread of tau pathology in the brainstem, 
spinal cord, and neocortex.
In conclusion, both Aβ and tau pathologies are necessary 
for the diagnosis of AD according to current criteria [17, 
22]. However, neuropathological data, presented in this 
paper, support the view that at the early phase only the tau 
component may be apparent. Tau deposition is a necessary 
but not sufficient pathology for the development of AD. We 
support the continued use of an assessment of NFT stages 
and Aβ phases (tau/Aβ), to which the CERAD score may 
be added [17, 22], without inference about the disease the 
patient would have developed if s/he had lived longer. This 
will facilitate correlations between clinical data, including 
biomarkers and neuroimaging, and pathology. We believe 
that the PART hypothesis does not add to the pathological 
description and may be confusing. It would be an improve-
ment if it were to have a prognostic value and if it could 
be demonstrated that PART arises through a pathogenic 
mechanism distinct from that of AD. At present, there is no 
evidence that PART and AD are the result of two entirely 
different processes.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
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